Arthur Krieg to Toll-Like Receptor 9
This is a "connection" page, showing publications Arthur Krieg has written about Toll-Like Receptor 9.
Connection Strength
4.128
-
Vollmer J, Krieg AM. Immunotherapeutic applications of CpG oligodeoxynucleotide TLR9 agonists. Adv Drug Deliv Rev. 2009 Mar 28; 61(3):195-204.
Score: 0.281
-
Kline JN, Krieg AM. Toll-like receptor 9 activation with CpG oligodeoxynucleotides for asthma therapy. Drug News Perspect. 2008 Oct; 21(8):434-9.
Score: 0.276
-
Krieg AM, Lipford GB. Immunology. The toll of cathepsin K deficiency. Science. 2008 Feb 01; 319(5863):576-7.
Score: 0.263
-
Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008 Jan 07; 27(2):161-7.
Score: 0.262
-
Krieg AM. Antiinfective applications of toll-like receptor 9 agonists. Proc Am Thorac Soc. 2007 Jul; 4(3):289-94.
Score: 0.253
-
Krieg AM. TLR9 and DNA 'feel' RAGE. Nat Immunol. 2007 May; 8(5):475-7.
Score: 0.250
-
Krieg AM. Development of TLR9 agonists for cancer therapy. J Clin Invest. 2007 May; 117(5):1184-94.
Score: 0.250
-
Krieg AM. Therapeutic potential of Toll-like receptor 9 activation. Nat Rev Drug Discov. 2006 Jun; 5(6):471-84.
Score: 0.234
-
McCluskie MJ, Krieg AM. Enhancement of infectious disease vaccines through TLR9-dependent recognition of CpG DNA. Curr Top Microbiol Immunol. 2006; 311:155-78.
Score: 0.228
-
Ribas A, Medina T, Kirkwood JM, Zakharia Y, Gonzalez R, Davar D, Chmielowski B, Campbell KM, Bao R, Kelley H, Morris A, Mauro D, Wooldridge JE, Luke JJ, Weiner GJ, Krieg AM, Milhem MM. Overcoming PD-1 Blockade Resistance with CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients with Metastatic Melanoma. Cancer Discov. 2021 12 01; 11(12):2998-3007.
Score: 0.172
-
Lemke-Miltner CD, Blackwell SE, Yin C, Krug AE, Morris AJ, Krieg AM, Weiner GJ. Antibody Opsonization of a TLR9 Agonist-Containing Virus-like Particle Enhances In Situ Immunization. J Immunol. 2020 03 01; 204(5):1386-1394.
Score: 0.151
-
Nichani AK, Dar MA, Mirakhur KK, Krieg AM, Booth JS, Townsend HG, Potter AA, Babiuk LA, Mutwiri GK. Subcutaneous, but not intratracheal administration of the TLR9 agonist, CpG DNA transiently reduces parainfluenza-3 virus shedding in newborn lambs. Comp Immunol Microbiol Infect Dis. 2010 Dec; 33(6):e111-7.
Score: 0.078
-
Vicari AP, Luu R, Zhang N, Patel S, Makinen SR, Hanson DC, Weeratna RD, Krieg AM. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol Immunother. 2009 Apr; 58(4):615-28.
Score: 0.069
-
Manegold C, Gravenor D, Woytowitz D, Mezger J, Hirsh V, Albert G, Al-Adhami M, Readett D, Krieg AM, Leichman CG. Randomized phase II trial of a toll-like receptor 9 agonist oligodeoxynucleotide, PF-3512676, in combination with first-line taxane plus platinum chemotherapy for advanced-stage non-small-cell lung cancer. J Clin Oncol. 2008 Aug 20; 26(24):3979-86.
Score: 0.068
-
Bhan U, Trujillo G, Lyn-Kew K, Newstead MW, Zeng X, Hogaboam CM, Krieg AM, Standiford TJ. Toll-like receptor 9 regulates the lung macrophage phenotype and host immunity in murine pneumonia caused by Legionella pneumophila. Infect Immun. 2008 Jul; 76(7):2895-904.
Score: 0.067
-
Dar A, Nichani AK, Benjamin P, Lai K, Soita H, Krieg AM, Potter A, Babiuk LA, Mutwiri GK. Attenuated cytokine responses in porcine lymph node cells stimulated with CpG DNA are associated with low frequency of IFNalpha-producing cells and TLR9 mRNA expression. Vet Immunol Immunopathol. 2008 Jun 15; 123(3-4):324-36.
Score: 0.066
-
Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity to autoimmunity. Immunol Rev. 2007 Dec; 220:251-69.
Score: 0.065
-
Bhan U, Lukacs NW, Osterholzer JJ, Newstead MW, Zeng X, Moore TA, McMillan TR, Krieg AM, Akira S, Standiford TJ. TLR9 is required for protective innate immunity in Gram-negative bacterial pneumonia: role of dendritic cells. J Immunol. 2007 Sep 15; 179(6):3937-46.
Score: 0.064
-
Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, Krieg AM, Levy R. Lymphoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 either in the host or in the tumor itself. J Immunol. 2007 Aug 15; 179(4):2493-500.
Score: 0.064
-
Vicari AP, Schmalbach T, Lekstrom-Himes J, Morris ML, Al-Adhami MJ, Laframboise C, Leese P, Krieg AM, Efler SM, Davis HL. Safety, pharmacokinetics and immune effects in normal volunteers of CPG 10101 (ACTILON), an investigational synthetic toll-like receptor 9 agonist. Antivir Ther. 2007; 12(5):741-51.
Score: 0.061
-
Pashenkov M, Go?ss G, Wagner C, H?rmann M, Jandl T, Moser A, Britten CM, Smolle J, Koller S, Mauch C, Tantcheva-Poor I, Grabbe S, Loquai C, Esser S, Franckson T, Schneeberger A, Haarmann C, Krieg AM, Stingl G, Wagner SN. Phase II trial of a toll-like receptor 9-activating oligonucleotide in patients with metastatic melanoma. J Clin Oncol. 2006 Dec 20; 24(36):5716-24.
Score: 0.061
-
Popovic PJ, DeMarco R, Lotze MT, Winikoff SE, Bartlett DL, Krieg AM, Guo ZS, Brown CK, Tracey KJ, Zeh HJ. High mobility group B1 protein suppresses the human plasmacytoid dendritic cell response to TLR9 agonists. J Immunol. 2006 Dec 15; 177(12):8701-7.
Score: 0.061
-
Jurk M, Kritzler A, Debelak H, Vollmer J, Krieg AM, Uhlmann E. Structure-activity relationship studies on the immune stimulatory effects of base-modified CpG toll-like receptor 9 agonists. ChemMedChem. 2006 Sep; 1(9):1007-14.
Score: 0.060
-
Montoya CJ, Jie HB, Al-Harthi L, Mulder C, Pati?o PJ, Rugeles MT, Krieg AM, Landay AL, Wilson SB. Activation of plasmacytoid dendritic cells with TLR9 agonists initiates invariant NKT cell-mediated cross-talk with myeloid dendritic cells. J Immunol. 2006 Jul 15; 177(2):1028-39.
Score: 0.059
-
Krieg AM, Efler SM, Wittpoth M, Al Adhami MJ, Davis HL. Induction of systemic TH1-like innate immunity in normal volunteers following subcutaneous but not intravenous administration of CPG 7909, a synthetic B-class CpG oligodeoxynucleotide TLR9 agonist. J Immunother. 2004 Nov-Dec; 27(6):460-71.
Score: 0.053
-
Vollmer J, Weeratna RD, Jurk M, Samulowitz U, McCluskie MJ, Payette P, Davis HL, Schetter C, Krieg AM. Oligodeoxynucleotides lacking CpG dinucleotides mediate Toll-like receptor 9 dependent T helper type 2 biased immune stimulation. Immunology. 2004 Oct; 113(2):212-23.
Score: 0.052
-
Vollmer J, Weeratna RD, Jurk M, Davis HL, Schetter C, W?llner M, Wader T, Liu M, Kritzler A, Krieg AM. Impact of modifications of heterocyclic bases in CpG dinucleotides on their immune-modulatory activity. J Leukoc Biol. 2004 Sep; 76(3):585-93.
Score: 0.051
-
Vollmer J, Rankin R, Hartmann H, Jurk M, Samulowitz U, Wader T, Janosch A, Schetter C, Krieg AM. Immunopharmacology of CpG oligodeoxynucleotides and ribavirin. Antimicrob Agents Chemother. 2004 Jun; 48(6):2314-7.
Score: 0.051
-
Krieg AM. Antitumor applications of stimulating toll-like receptor 9 with CpG oligodeoxynucleotides. Curr Oncol Rep. 2004 Mar; 6(2):88-95.
Score: 0.050
-
Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, Wader T, Tluk S, Liu M, Davis HL, Krieg AM. Characterization of three CpG oligodeoxynucleotide classes with distinct immunostimulatory activities. Eur J Immunol. 2004 Jan; 34(1):251-62.
Score: 0.050
-
Vollmer J, Jurk M, Samulowitz U, Lipford G, Forsbach A, W?llner M, Tluk S, Hartmann H, Kritzler A, M?ller C, Schetter C, Krieg AM. CpG oligodeoxynucleotides stimulate IFN-gamma-inducible protein-10 production in human B cells. J Endotoxin Res. 2004; 10(6):431-8.
Score: 0.050
-
Krieg AM. CpG motifs: the active ingredient in bacterial extracts? Nat Med. 2003 Jul; 9(7):831-5.
Score: 0.048
-
Krieg AM. A role for Toll in autoimmunity. Nat Immunol. 2002 May; 3(5):423-4.
Score: 0.044
-
Krieg AM. From A to Z on CpG. Trends Immunol. 2002 Feb; 23(2):64-5.
Score: 0.043
-
Krieg AM. Now I know my CpGs. Trends Microbiol. 2001 Jun; 9(6):249-52.
Score: 0.041
-
Karan D, Krieg AM, Lubaroff DM. Paradoxical enhancement of CD8 T cell-dependent anti-tumor protection despite reduced CD8 T cell responses with addition of a TLR9 agonist to a tumor vaccine. Int J Cancer. 2007 Oct 01; 121(7):1520-8.
Score: 0.016
-
Martinson JA, Tenorio AR, Montoya CJ, Al-Harthi L, Gichinga CN, Krieg AM, Baum LL, Landay AL. Impact of class A, B and C CpG-oligodeoxynucleotides on in vitro activation of innate immune cells in human immunodeficiency virus-1 infected individuals. Immunology. 2007 Apr; 120(4):526-35.
Score: 0.016
-
Abel K, Wang Y, Fritts L, Sanchez E, Chung E, Fitzgerald-Bocarsly P, Krieg AM, Miller CJ. Deoxycytidyl-deoxyguanosine oligonucleotide classes A, B, and C induce distinct cytokine gene expression patterns in rhesus monkey peripheral blood mononuclear cells and distinct alpha interferon responses in TLR9-expressing rhesus monkey plasmacytoid dendritic cells. Clin Diagn Lab Immunol. 2005 May; 12(5):606-21.
Score: 0.014
-
Edwards L, Williams AE, Krieg AM, Rae AJ, Snelgrove RJ, Hussell T. Stimulation via Toll-like receptor 9 reduces Cryptococcus neoformans-induced pulmonary inflammation in an IL-12-dependent manner. Eur J Immunol. 2005 Jan; 35(1):273-81.
Score: 0.013
-
Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, Whisnant JK, Milas L. Targeting toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor response to fractionated radiotherapy. Clin Cancer Res. 2005 Jan 01; 11(1):361-9.
Score: 0.013
-
Cooper CL, Davis HL, Morris ML, Efler SM, Adhami MA, Krieg AM, Cameron DW, Heathcote J. CPG 7909, an immunostimulatory TLR9 agonist oligodeoxynucleotide, as adjuvant to Engerix-B HBV vaccine in healthy adults: a double-blind phase I/II study. J Clin Immunol. 2004 Nov; 24(6):693-701.
Score: 0.013
-
Pichyangkul S, Yongvanitchit K, Kum-arb U, Hemmi H, Akira S, Krieg AM, Heppner DG, Stewart VA, Hasegawa H, Looareesuwan S, Shanks GD, Miller RS. Malaria blood stage parasites activate human plasmacytoid dendritic cells and murine dendritic cells through a Toll-like receptor 9-dependent pathway. J Immunol. 2004 Apr 15; 172(8):4926-33.
Score: 0.013
-
Marshak-Rothstein A, Busconi L, Lau CM, Tabor AS, Leadbetter EA, Akira S, Krieg AM, Lipford GB, Viglianti GA, Rifkin IR. Comparison of CpG s-ODNs, chromatin immune complexes, and dsDNA fragment immune complexes in the TLR9-dependent activation of rheumatoid factor B cells. J Endotoxin Res. 2004; 10(4):247-51.
Score: 0.012
-
Jurk M, Schulte B, Kritzler A, Noll B, Uhlmann E, Wader T, Schetter C, Krieg AM, Vollmer J. C-Class CpG ODN: sequence requirements and characterization of immunostimulatory activities on mRNA level. Immunobiology. 2004; 209(1-2):141-54.
Score: 0.012
-
Krug A, Towarowski A, Britsch S, Rothenfusser S, Hornung V, Bals R, Giese T, Engelmann H, Endres S, Krieg AM, Hartmann G. Toll-like receptor expression reveals CpG DNA as a unique microbial stimulus for plasmacytoid dendritic cells which synergizes with CD40 ligand to induce high amounts of IL-12. Eur J Immunol. 2001 Oct; 31(10):3026-37.
Score: 0.011